Isotopologues of isoindole derivatives
Provided herein are isoindole derivatives, which is enriched with isotopes such as deuterium. Pharmaceutical compositions comprising the isotopes-enriched compounds, and methods of using such compounds are also provided.
1. A compound of formula:
or a pharmaceutically acceptable salt thereof, wherein:
at least one of Y 1 -Y 25 is a hydrogen that is isotopically enriched with deuterium, and the others of Y 1 -Y 25 are non-enriched hydrogen atoms.
2. The compound of claim 1 , wherein the compound is an (S)-isomer having a structure:
3. The compound of claim 1 , wherein one to five of Y 1 -Y 25 is isotopically enriched with deuterium, and the others are non-enriched hydrogens.
4. The compound of claim 1 , wherein six to ten of Y 1 -Y 25 are isotopically enriched with deuterium, and the others are non-enriched hydrogens.
5. The compound of claim 1 , wherein eleven to fifteen of Y 1 -Y 25 are isotopically enriched with deuterium, and the others are non-enriched hydrogens.
6. The compound of claim 1 , wherein sixteen to twenty of Y 1 -Y 25 are isotopically enriched with deuterium, and the others are non-enriched hydrogens.
7. The compound of claim 1 , wherein twenty one to twenty five of Y 1 -Y 25 are isotopically enriched with deuterium, and the others are non- enriched hydrogens.
8. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof.
9. A method of inhibiting TNFαor PDE4 levels in a patient comprising administering to a patient a compound of claim 1 , or a pharmaceutically acceptable salt or thereof.
10. The method of claim 9 , further comprising administering a second active agent selected from prednisone, salicylic acid acetate, clarithromycin, bortezomib, and dexamethasone.